BCL2 and cancer: Furthermore, concurrent involvement of both Ras and Bcl-2 pathways is observed in various other drug-resistant cancer models, such as imatinib-resistant acute lymphoblastic leukemia with Philadelphia chromosome (Ph+ ALL; Suzuki et al., 2010), both cisplatin- and paclitaxel-resistant ovarian cancer (Wang et al., 2010) as well as VP-16- and cisplatin-resistant prostate cancer (Sinha et al., 1995).